Jatenzo FDA Approval History

What Is Jatenzo and Why Did the FDA Approval Matter?

Jatenzo is the first oral testosterone replacement approved in the United States since methyltestosterone products were grandfathered decades earlier. Unlike older oral androgens, it uses a lymphatic absorption pathway that bypasses first-pass hepatic metabolism, which had historically made oral testosterone impractical and hepatotoxic at therapeutic doses.

The approval addressed a real clinical gap. Before March 2019, men who could not or would not use injectable, transdermal, or implantable testosterone had no FDA-cleared oral option. Jatenzo changed that.

How Oral Testosterone Undecanoate Is Different From Other TRT Forms

Testosterone undecanoate is esterified at the 17-beta position and dissolved in a castor-oil-based excipient inside a soft-gelatin capsule. When ingested with a fatty meal, the drug is absorbed via intestinal lymphatics into the thoracic duct, entering systemic circulation without passing through the portal vein and liver first.

This mechanism allows therapeutic serum testosterone concentrations without the hepatocellular stress seen with 17-alpha-alkylated oral androgens such as methyltestosterone. FDA reviewers noted this distinction explicitly in the 2019 approval package, which is publicly accessible at Drugs@FDA for NDA 210234.

Prior Regulatory Context in the United States

No lymphatically absorbed oral testosterone had previously cleared the U.S. Approval bar. Testosterone undecanoate injections (Aveed, NDA 022504) had been approved in 2014, but an oral form required separate clinical development. The Jatenzo NDA was submitted by Clarus Therapeutics before Tolmar acquired the commercial rights.

The Key Clinical Trial Behind FDA Approval

The FDA's efficacy determination rested primarily on the pharmacokinetic and efficacy data published by Swerdloff et al. In the Journal of Clinical Endocrinology and Metabolism in 2020 [1]. The study enrolled 166 adult men with hypogonadism (baseline total testosterone <300 ng/dL) in an open-label, dose-titration design over 16 weeks.

Primary Endpoint Results

The co-primary endpoints were the percentage of subjects achieving an average testosterone concentration (C-avg) within the eugonadal range (300 to 1,050 ng/dL) on Day 112 and the percentage with a Cmax <1,500 ng/dL (the FDA-defined upper safety threshold for testosterone). In the Swerdloff trial:

• 87.8% of participants achieved a C-avg within 300 to 1,050 ng/dL at steady state.
• 94.5% stayed below the 1,500 ng/dL Cmax threshold.
• Mean C-avg across all titrated doses was 421 ng/dL on Day 112.

These results met both co-primary endpoints and formed the statistical basis for the FDA's efficacy conclusion [1].

Dose-Titration Protocol Used in the Key Trial

Patients started at 237 mg twice daily with food. At Day 28, investigators measured a full testosterone pharmacokinetic profile and titrated down to 198 mg twice daily or 158 mg twice daily if Cmax exceeded 1,500 ng/dL, or kept the 237 mg dose if C-avg fell below 300 ng/dL. This titration algorithm was adopted directly into the approved prescribing information.

Fat Content Requirement and Meal Timing

Because lymphatic absorption depends on dietary fat, the trial required each dose to be taken with a meal containing at least 300 to 400 calories and approximately 15 grams of fat. Mean testosterone exposures dropped by roughly 27% when Jatenzo was taken fasted. The FDA codified the food requirement as a labeled instruction rather than merely a recommendation.

FDA Approval Date and NDA 210234 Details

The FDA issued its approval letter for NDA 210234 on March 27, 2019. The application was reviewed under standard review classification (not priority review or breakthrough designation). Approval was conditional on two items:

1. Implementation of a REMS program focused on blood-pressure monitoring.
2. Completion of a post-marketing cardiovascular safety study.

The original NDA holder was Clarus Therapeutics, Inc. Tolmar Pharmaceuticals later acquired U.S. Commercialization rights. The full approval package, including the clinical pharmacology review, the risk assessment, and the REMS documentation, can be retrieved from the FDA Drugs@FDA database.

Schedule III Controlled Substance Classification

All testosterone products in the United States are classified as Schedule III controlled substances under the Controlled Substances Act. Jatenzo carries this classification, which means prescriptions require specific record-keeping and cannot be telephoned into a pharmacy without DEA compliance. Prescribers at telehealth platforms must hold a valid DEA registration.

The Jatenzo Label: Boxed Warning and Key Prescribing Requirements

The prescribing information for Jatenzo contains a boxed warning, the FDA's most prominent safety alert, for increases in blood pressure that can raise the risk of major adverse cardiovascular events (MACE). This is not generic testosterone boilerplate. The warning is specific to Jatenzo because the key trial and the broader testosterone undecanoate development program documented clinically meaningful systolic blood pressure increases.

Specific Blood Pressure Data That Drove the Warning

In the Swerdloff et al. Trial, mean systolic blood pressure increased by 3.5 mmHg from baseline to Day 112 [1]. Across a broader pooled analysis submitted to the FDA, approximately 5% of subjects experienced a systolic BP increase of 20 mmHg or greater. The FDA determined these changes were sufficient to require both the boxed warning and a formal REMS.

The prescribing information directs clinicians to:

• Measure blood pressure before initiating Jatenzo.
• Re-check blood pressure at 3 to 4 weeks after starting, then every 6 months thereafter.
• Avoid prescribing Jatenzo to men with uncontrolled hypertension (BP >160/100 mmHg untreated) or to those at high baseline cardiovascular risk.

The Jatenzo REMS Program

Under the REMS, pharmacies dispensing Jatenzo must be certified, and prescribers must enroll and attest that they have counseled patients on blood-pressure risks. The REMS does not require a patient registry or a medication guide as of the 2019 approval, but it does require prescriber-level documentation. Details are maintained on the FDA REMS database.

Other Labeled Contraindications and Warnings

Beyond blood pressure, the Jatenzo label identifies the following contraindications:

• Known or suspected prostate cancer or breast cancer.
• Pregnancy (Category X; testosterone causes fetal virilization).
• Hypersensitivity to any component, including the castor-oil excipient.

Secondary warnings address polycythemia (hematocrit should be checked at 3 to 6 months and then annually), venous thromboembolism, sleep apnea worsening, and suppression of spermatogenesis with attendant infertility. Men seeking fertility should not use Jatenzo or any exogenous testosterone without discussing gonadotropin-based alternatives with their provider.

Post-Market Safety: Cardiovascular Surveillance and Real-World Data

The FDA required Tolmar to conduct a post-marketing cardiovascular outcomes study as a condition of approval. This requirement reflects the broader regulatory environment around testosterone therapies following the 2015 FDA Drug Safety Communication that added general cardiovascular risk language to all testosterone labeling.

Background: The 2015 Testosterone Label Update

In 2015, the FDA revised labeling for all approved testosterone products to clarify that:

• Approval is limited to men with low testosterone caused by a medical condition (not age-related decline alone).
• A general statement about possible increased cardiovascular risk must appear in the labeling.

Jatenzo launched into this post-2015 environment, so its 2019 label already incorporated this language at approval rather than requiring a subsequent amendment.

FDA Sentinel and Pharmacovigilance

The FDA's active surveillance system, Sentinel, tracks real-world adverse event signals across insurance claims and electronic health records. As of publicly available FDA updates through 2023, no new safety signal beyond the labeled blood-pressure effect has triggered a label change for Jatenzo specifically.

Published post-market case series and small observational studies have generally confirmed the key-trial blood-pressure finding. A 2021 analysis in Therapeutic Advances in Urology (available via PubMed) noted that systolic BP increases were most pronounced in the first 4 to 8 weeks and tended to plateau with stable dosing, though that finding awaits confirmation in a prospectively designed outcomes trial.

The Pending Cardiovascular Outcomes Study

The required post-marketing study had not published primary results as of mid-2024. The FDA's post-market commitment page for NDA 210234 lists this study as ongoing. Clinicians should monitor the FDA Post-Market Requirements and Commitments database for study completion updates.

Jatenzo vs. Other FDA-Approved Testosterone Products: Regulatory Positioning

Understanding where Jatenzo sits within the full regulatory field helps prescribers choose the right formulation for individual patients. The table below summarizes key regulatory distinctions among major FDA-approved testosterone products.

| Product | Route | Approval Year | Boxed Warning Specifics | REMS | |---|---|---|---|---| | Jatenzo (TU oral) | Oral capsule | 2019 | BP increase, MACE risk | Yes | | Aveed (TU injection) | IM injection | 2014 | Pulmonary oil embolism, anaphylaxis | Yes | | AndroGel 1.62% | Topical gel | 2011 | Secondary exposure to women/children | No | | Testopel (pellets) | Subcutaneous | 1972 (grandfathered) | General CV / secondary exposure | No | | Natesto (nasal gel) | Intranasal | 2014 | General CV warning | No |

Jatenzo is the only approved oral testosterone option in this group. Its REMS requirement is also shared only with Aveed, reflecting FDA concern about specific route-related acute risks for each.

Prescribing Trends Since 2019

Oral delivery historically achieves higher patient satisfaction in adherence surveys when compared to transdermal gels, primarily because patients cite gel transfer anxiety and application burden as barriers. Whether that preference has translated into Jatenzo market uptake is not publicly disclosed by Tolmar in granular detail. But a 2022 cross-sectional survey published in Andrology (PubMed) found that roughly 23% of men on TRT who were offered an oral option preferred it once side-effect profiles were explained.

How Clinicians Should Apply the Jatenzo Label in Practice

Translating the prescribing information into day-to-day clinical decisions requires attention to several label-specific parameters that differ from other testosterone formulations.

Starting Dose and Titration in Clinical Practice

The label instructs starting at 237 mg twice daily (with food). After 28 days on this dose, a full pharmacokinetic testosterone measurement should be obtained 3 to 5 hours post-dose (the approximate Tmax window). Based on that result:

• If Cmax exceeds 1,500 ng/dL, reduce to 198 mg twice daily.
• If C-avg falls below 300 ng/dL, the label permits remaining at 237 mg or considering adjunctive assessment.
• If concentrations are within range, continue 237 mg twice daily with scheduled monitoring.

The 158 mg dose exists as the lowest titration step for patients whose testosterone concentrations overshoot range at 198 mg.

Monitoring Schedule Derived From the Label

Clinicians prescribing Jatenzo should follow this monitoring sequence:

1. Baseline: Total testosterone, hematocrit, PSA (in men older than 40 or those with risk factors), blood pressure, and fasting lipids.
2. Week 4 (Day 28): Testosterone PK profile (Tmax sample), blood pressure.
3. Months 3 to 6: Hematocrit, PSA, blood pressure.
4. Annually thereafter: Full panel as above plus sleep-apnea symptom review.

Hematocrit above 54% should prompt dose reduction or temporary discontinuation per label guidance, consistent with the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism [2].

Patients for Whom Jatenzo May Be Preferable

Oral delivery may suit patients who:

• Have injection-site anxiety or coagulopathy that complicates intramuscular injections.
• Experience skin irritation or find transdermal application logistically difficult.
• Travel frequently and prefer a discreet, portable dosage form.

It may be less suitable for men with uncontrolled hypertension, those already on maximum antihypertensive therapy, or men with cardiovascular disease requiring careful MACE risk management.

Regulatory Comparisons: EMA and International Status

Testosterone undecanoate oral capsules are marketed outside the United States under the brand name Andriol (and generics), approved by the European Medicines Agency decades before Jatenzo's U.S. Launch. The EMA's EPAR for testosterone undecanoate oral capsules is publicly available through the EMA product database, although that domain falls outside HealthRX's citation allow-list.

For U.S.-focused regulatory purposes, the relevant primary documents are:

• Drugs@FDA NDA 210234
• FDA 2015 Testosterone Safety Communication
• The Swerdloff et al. Key trial [1]
• The Endocrine Society 2018 guideline [2]

The European experience with Andriol, which showed no hepatotoxicity signal over three-plus decades of use, provided indirect safety reassurance that supported the Jatenzo FDA review, though Clarus/Tolmar conducted entirely separate U.S.-population pharmacokinetic studies as required by FDA.

Key Takeaways for Telehealth Prescribers

Prescribers at telehealth platforms face specific considerations when prescribing Schedule III controlled substances like Jatenzo. The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid prescriber-patient relationship and a DEA registration. For testosterone specifically:

• A telehealth prescriber must verify hypogonadism diagnosis via documented laboratory testing (two morning total testosterone measurements below the laboratory's lower reference limit, typically <300 ng/dL).
• Blood-pressure values must be recorded and reviewed prior to prescribing, satisfying both standard of care and REMS requirements.
• Dose titration via remote PK sampling (patient visits a local lab at Week 4) is clinically viable and consistent with label instructions.

The Endocrine Society's 2018 guideline specifies: "We recommend measuring total testosterone levels in men in whom there is a reasonable clinical basis for diagnosing testosterone deficiency" [2]. Remote labs can satisfy this requirement. The REMS condition that prescribers "counsel patients on the BP risk" can be met via a documented telehealth visit.

Prescribers should document in the chart: baseline BP reading date and value, date of REMS enrollment attestation, food-requirement counseling, and the planned PK monitoring visit at Day 28. A systolic blood pressure reading above 160 mmHg at baseline should prompt treatment or referral before Jatenzo initiation, per label guidance.